Human Molecular Genetics Advance Access published online on November 12, 2003
Human Molecular Genetics, doi:10.1093/hmg/ddh011
© 2003 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Pharmacology, New York University School of Medicine, New York, NY 10016, USA
* To whom correspondence should be addressed. E-mail: mohammad{at}saturn.med.nyu.edu.
Identical Proline
Article
Proline to Arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity
2 Department of Chemistry, Biology, and Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, NY, 12180, USA
Abstract 
Arginine gain-of-function mutations in fibroblast growth factor receptor (FGFR) 1 (Pro252Arg), FGFR2 (Pro253Arg) and FGFR3 (Pro250Arg), result in type I Pfeiffer, Apert and Muenke craniosynostosis syndromes, respectively. Here, we characterize the effects of Proline Arginine mutations in FGFR1c and FGFR3c on ligand binding using surface plasmon resonance and X-ray crystallography. Both Pro252Arg FGFR1c and Pro250Arg FGFR3c exhibit an enhancement in ligand binding in comparison to their respective wild-type receptors. Interestingly, binding of both mutant receptors to FGF9 was notably enhanced and implicates FGF9 as a potential pathophysiological ligand for mutant FGFRs in mediating craniosynostosis. The crystal structure, of Pro252Arg FGFR1c in complex with FGF2, demonstrates that the enhanced ligand binding is due to an additional set of receptor-ligand hydrogen bonds, similar to those gain-of-function interactions that occur in the Apert syndrome Pro253Arg FGFR2c-FGF2 crystal structure. However, unlike the Apert syndrome Pro253Arg FGFR2c mutant, neither the Pfeiffer syndrome Pro250Arg FGFR1c mutant nor the Muenke syndrome Pro250Arg FGFR3c mutant bound appreciably to FGF7 or FGF10. This observation provides a potential explanation for why the limb phenotypes, observed in type I Pfeiffer and Muenke syndromes, are less severe than the limb abnormalities observed in Apert syndrome. Hence, although analogous Proline Arginine mutations in FGFR1-3 act through a common structural mechanism to result in gain-of-function, differences in the primary sequence among FGFRs result in varying effects on ligand binding specificity.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. L. Mansour, S. R.F. Twigg, R. M. Freeland, S. A. Wall, C. Li, and A. O.M. Wilkie Hearing loss in a mouse model of Muenke syndrome Hum. Mol. Genet., January 1, 2009; 18(1): 43 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Z. Zhao, P. M. Pollock, S. Thomas, S. A. Treloar, D. R. Nyholt, and G. W. Montgomery Common variation in the fibroblast growth factor receptor 2 gene is not associated with endometriosis risk Hum. Reprod., July 1, 2008; 23(7): 1661 - 1668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nakayama, N. Mutsuga, and G. Tosato FGF2 posttranscriptionally down-regulates expression of SDF1 in bone marrow stromal cells through FGFR1 IIIc Blood, February 15, 2007; 109(4): 1363 - 1372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Olsen, J. Y.H. Li, C. Bromleigh, A. V. Eliseenkova, O. A. Ibrahimi, Z. Lao, F. Zhang, R. J. Linhardt, A. L. Joyner, and M. Mohammadi Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain Genes & Dev., January 15, 2006; 20(2): 185 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Yu, O. A. Ibrahimi, R. Goetz, F. Zhang, S. I. Davis, H. J. Garringer, R. J. Linhardt, D. M. Ornitz, M. Mohammadi, and K. E. White Analysis of the Biochemical Mechanisms for the Endocrine Actions of Fibroblast Growth Factor-23 Endocrinology, November 1, 2005; 146(11): 4647 - 4656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. A. Ibrahimi, B. K. Yeh, A. V. Eliseenkova, F. Zhang, S. K. Olsen, M. Igarashi, S. A. Aaronson, R. J. Linhardt, and M. Mohammadi Analysis of Mutations in Fibroblast Growth Factor (FGF) and a Pathogenic Mutation in FGF Receptor (FGFR) Provides Direct Evidence for the Symmetric Two-End Model for FGFR Dimerization Mol. Cell. Biol., January 15, 2005; 25(2): 671 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. A. Ibrahimi, F. Zhang, A. V. Eliseenkova, N. Itoh, R. J. Linhardt, and M. Mohammadi Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities Hum. Mol. Genet., October 1, 2004; 13(19): 2313 - 2324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Olsen, O. A. Ibrahimi, A. Raucci, F. Zhang, A. V. Eliseenkova, A. Yayon, C. Basilico, R. J. Linhardt, J. Schlessinger, and M. Mohammadi Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity PNAS, January 27, 2004; 101(4): 935 - 940. [Abstract] [Full Text] [PDF]
|
|